Shilpa Medicare partners with Orion for Nivolumab biosimilar in Europe
Shilpa Biologicals will develop and supply the biosimilar; Orion handles EU regulatory and marketing. Originator Nivolumab had $4.1B in European sales in 2025.
— 6 earlier stories on Shilpa Medicare Ltd. →What's new
- Shilpa Biologicals signs co-development and supply deal with Orion for a Nivolumab biosimilar.
- Shilpa will lead development and be exclusive long-term supplier; Orion holds marketing rights in Europe.
- Milestone payments plus supply revenue, but deal value undisclosed.
Why this matters
Nivolumab is a blockbuster immuno-oncology drug nearing loss of exclusivity in Europe. For Shilpa, a mid-cap with ₹11,179 cr market cap and trailing revenue of ₹437 cr, locking in a partner with Orion's commercial reach opens a material revenue stream in biosimilars, complementing its recent ADC facility and biologics CDMO push.
What we're watching
- Regulatory milestones and timeline for European approval.
- Visibility on deal economics when Shilpa discloses milestones.
- Integration with Shilpa's Dharwad biologics capacity and ongoing CDMO ramp.
The full read
Shilpa Medicare's subsidiary has signed a co-development and supply deal with Finnish pharma Orion Corporation for a Nivolumab biosimilar. Shilpa Biologicals will develop and manufacture at its Dharwad facility; Orion holds the marketing rights and will be the Marketing Authorisation holder in Europe. The target market: originator Nivolumab's $4.1 billion in European sales as it loses exclusivity. Shilpa gets milestone payments plus long-term supply revenue—undisclosed. That's the prize. The deal builds on Shilpa's recent ₹437 cr quarterly revenue and its expansion into biologics CDMO, including a new ADC facility. For a mid-cap with ₹11,179 cr market cap, the partnership validates manufacturing capabilities and opens a high-value pipeline. The open question is how much of that $4.1B market the pair can capture.
Questions answered
- What is the financial structure of the deal?
- Shilpa receives development and regulatory milestone payments plus long-term supply revenue. Financial terms of the agreement were not disclosed.
- How big is the market for Nivolumab in Europe?
- Originator Nivolumab recorded approximately USD 4.1 billion in European sales in 2025. The market is large and approaching loss of exclusivity, creating a biosimilar opportunity.
- What are the roles of Shilpa and Orion?
- Shilpa Biologicals leads product development and manufacturing at its Dharwad facility and is the exclusive long-term supplier. Orion Corporation holds exclusive marketing rights and is the Marketing Authorization holder in Europe.
- How does this fit Shilpa's broader strategy?
- The deal extends Shilpa's biologics CDMO strategy, following its recent commissioning of an ADC facility and investment in a Spanish biotech. It marks entry into immuno-oncology biosimilars for a global market.
Shilpa Medicare Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on SHILPAMED →- 30 Jun 2026 · 10:26 AM IST Shilpa Medicare partners with Orion for Nivolumab biosimilar in Europe
- 12d ago Shilpa Medicare commissions ADC facility, targets global CDMO play
- 33d ago Shilpa Medicare buys 30% of Spanish biotech for €7M, chases a brain-cancer therapy
- 41d ago Shilpa Medicare drops Aflibercept Europe trial, delays alopecia drug
- 45d ago Shilpa Medicare kills European Aflibercept push, defers Unicycive revenue to FY28